Syndax Pharmaceuticals SNDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $217.42M+26.0% | $172.6M+54.7% | $111.55M+42.7% | $78.18M+78.8% | $43.72M+84.6% | ||
| $255.99M-1.1% | $258.78M+5.3% | $245.67M-5.6% | $260.36M+5.5% | $246.79M+2.1% | ||
| —— | $179.68M+8.9% | $164.98M+9.8% | $150.28M+10.8% | $135.58M+12.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $440.95M-1.1% | $445.68M+6.5% | $418.45M+0.3% | $417.23M+7.6% | $387.64M+6.7% | ||
| $440.95M-1.1% | $445.68M+6.5% | $418.45M+0.3% | $417.23M+7.6% | $387.64M+6.7% | ||
| -$223.53M+18.1% | -$273.08M+11.0% | -$306.9M+9.5% | -$339.05M+1.4% | -$343.92M-1.2% | ||
| -102.8%+55.4pp | -158.2%+117pp | -275.1%+159pp | -433.7%+353pp | -786.6%+648pp | ||
| $4K-33.3% | $6K+105% | -$118K-24.2% | -$95K-75.9% | -$54K-5,300% | ||
| $19.11M-15.9% | $22.73M-10.9% | $25.51M-0.7% | $25.68M-1.3% | $26.02M-0.3% | ||
| -$19.72M-59.8% | -$12.34M-164% | -$4.68M-215% | $4.06M-68.0% | $12.71M-39.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$243.25M+14.8% | -$285.42M+8.4% | -$311.58M+7.0% | -$334.99M-1.1% | -$331.2M-3.9% | ||
| -111.9%+53.5pp | -165.4%+114pp | -279.3%+149pp | -428.5%+329pp | -757.5%+589pp | ||
| -$2.79+15.2% | -$3.29+8.6% | -$3.60+7.2% | -$3.88-0.8% | -$3.85-3.5% | ||
| -$2.79+15.2% | -$3.29+8.6% | -$3.60+7.2% | -$3.88-0.8% | -$3.85-3.5% | ||
| 347.8M+0.6% | 345.8M+0.3% | 344.8M+0.3% | 343.6M+0.3% | 342.5M+0.3% | ||
| 347.8M+0.6% | 345.8M+0.3% | 344.8M+0.3% | 343.6M+0.3% | 342.5M+0.3% | ||
| —— | —— | —— | —— | —— | ||
| $37.58M+11.2% | $33.78M+16.0% | $29.12M+39.8% | $20.83M+60.5% | $12.98M+163% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $173K-24.5% | $229K-11.6% | $259K+31.5% | $197K+38.7% | $142K+373% | ||
| —— | —— | —— | —— | —— | ||
| $8.72M+25.1% | $6.97M+36.9% | $5.09M+70.2% | $2.99M+74.8% | $1.71M+107% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $5.79M+367% | $1.24M-25.6% | ||
| $22.15M-27.1% | $30.39M+19.6% | $25.4M+30.6% | $19.45M+23.7% | $15.72M+107% | ||
| —— | —— | —— | —— | —— | ||
| $16.35M-61.2% | $42.17M+49.9% | $28.13M-41.5% | $48.06M+106% | $23.32M+21.8% | ||
| —— | —— | —— | —— | —— | ||
| $29.96M-6.6% | $32.09M+30.2% | $24.66M+41.1% | $17.47M+283% | $4.56M+1,145% | ||
| $12.7M-12.7% | $14.54M— | —— | —— | —— | ||
| $20.66M+51.1% | $13.68M-96.1% | $355.18M+0.9% | $352M0.0% | $352.13M-0.4% | ||
| $234.28M-19.2% | $290.04M+579% | -$60.52M-31.3% | -$46.1M— | —— | ||
| -$278.16M+13.9% | -$322.98M-3.9% | -$310.88M-2.7% | -$302.67M-5.6% | -$286.52M-4.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.25M+2.7% | -$1.28M-8.0% | -$1.19M-34.8% | -$881K-131% | -$381K-54.3% | ||
| $224.66M+14.7% | $195.81M-61.5% | $509.01M+3.5% | $491.92M+22.9% | $400.21M-28.2% | ||
| $459.13M-5.5% | $486.03M+8.3% | $448.62M+0.6% | $445.82M+19.2% | $373.97M+10.9% | ||
| $19.21M+58.3% | $12.14M+21.8% | $9.97M+61.5% | $6.17M-5.5% | $6.53M-18.4% | ||
| $1.53M-5.4% | $1.62M-1.8% | $1.65M-24.5% | $2.18M+11.8% | $1.95M+13.8% | ||
| $217.42M+26.0% | $172.6M+54.7% | $111.55M+42.7% | $78.18M+78.8% | $43.72M+84.6% | ||
| $49.18M+3.5% | $47.5M-2.1% | $48.55M+0.3% | $48.4M+8.7% | $44.51M+3.4% | ||
| —— | —— | —— | —— | —— | ||
| -$223.53M+18.1% | -$273.08M+11.0% | -$306.9M+9.5% | -$339.05M+1.4% | -$343.92M-1.2% | ||
| —— | —— | —— | —— | —— | ||
| -$223.53M+18.1% | -$273.08M+11.0% | -$306.9M+9.5% | -$339.05M+1.4% | -$343.92M-1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Syndax Pharmaceuticals's revenue?
- Syndax Pharmaceuticals (SNDX) generated $217.4M in revenue over the trailing twelve months, up 397.3% year over year.
- Is Syndax Pharmaceuticals profitable?
- Syndax Pharmaceuticals is not currently profitable: it reported a net loss of $243.2M over the trailing twelve months, a -111.9% net margin.
- What is Syndax Pharmaceuticals's earnings per share?
- Syndax Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.79.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
